Correlation Between Denali Therapeutics and Exagen

Can any of the company-specific risk be diversified away by investing in both Denali Therapeutics and Exagen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Denali Therapeutics and Exagen into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Denali Therapeutics and Exagen Inc, you can compare the effects of market volatilities on Denali Therapeutics and Exagen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Denali Therapeutics with a short position of Exagen. Check out your portfolio center. Please also check ongoing floating volatility patterns of Denali Therapeutics and Exagen.

Diversification Opportunities for Denali Therapeutics and Exagen

-0.74

Correlation Coefficient

Denali Therapeutics  Exagen

Pay attention - limited upside

The 3 months correlation between Denali and Exagen is -0.74. Overlapping area represents the amount of risk that can be diversified away by holding Denali Therapeutics and Exagen Inc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Exagen Inc and Denali Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Denali Therapeutics are associated (or correlated) with Exagen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Exagen Inc has no effect on the direction of Denali Therapeutics i.e., Denali Therapeutics and Exagen go up and down completely randomly.

Pair Corralation between Denali Therapeutics and Exagen

Given the investment horizon of 90 days Denali Therapeutics is expected to under-perform the Exagen. But the stock apears to be less risky and, when comparing its historical volatility, Denali Therapeutics is 2.53 times less risky than Exagen. The stock trades about -0.18 of its potential returns per unit of risk. The Exagen Inc is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest  392.00  in Exagen Inc on September 22, 2024 and sell it today you would earn a total of  123.00  from holding Exagen Inc or generate 31.38% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Denali Therapeutics  vs.  Exagen Inc

Denali Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Denali Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in January 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Exagen Inc

Risk-Adjusted Performance

12 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Exagen Inc are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, Exagen displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Denali Therapeutics and Exagen

The main advantage of trading using opposite Denali Therapeutics and Exagen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Denali Therapeutics position performs unexpectedly, Exagen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will offset losses from the drop in Exagen's long position.

The idea behind Denali Therapeutics and Exagen Inc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.